Symbols

ORGO

Organogenesis·NASDAQ

--(--)

ORGO fundamentals

ORGO Q4 2025 Earnings

Organogenesis (ORGO) released its earnings on Feb 26, 2026: revenue was 225.61M (YoY +78.13%), beat estimates; EPS was 0.3096 (YoY +674.00%), beat estimates.

Revenue / YoY

225.61M

+78.13%

EPS / YoY

0.3096

+674.00%

Report date

Feb 26, 2026

ORGO Earnings Call Summary for Q4,2025

Q4 2025 Record Performance: $225.1M revenue (+78% YoY), driven by 83% AWC growth and 12% SSM expansion.
2026 Outlook: 25%-38% YoY revenue decline due to CMS policy disruption, but 2H26 recovery with 4Q26 EBITDA >15%.
Strategic Investments: RI manufacturing facility, ReNu BLA submission, and clinical evidence expansion to capitalize on CMS reforms.
Key Risk: Clinician confusion over CMS comments on discarded products and $127 reimbursement rate reduction.

Earnings

EPS

Revenue

Revenue & Expenses

ORGO has released its 2025 Q4 earnings report, with revenue of 225.61M, reflecting a YoY change of 78.13%, and net profit of 43.70M, showing a YoY change of 469.53%. The Sankey diagram below clearly presents ORGO's revenue sources and cost distribution.

Key Indicators

Organogenesis (ORGO) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Organogenesis (ORGO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Organogenesis (ORGO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Organogenesis (ORGO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown